
Keywords: PCR; Circulating tumor DNA; Liquid biopsy; Intra-tumor heterogeneity; Disease monitoring; Molecular resistance; Early detectionctDNA, circulating tumor DNA; MPS, massive parallel sequencing; MRD, minimal residual disease; NGS, Next Generation Sequencing; PCR,